Bringing Mirvetuximab Soravtansine, an FR-alpha Directed ADC, to Patients with Ovarian Cancer
Time: 9:00 am
day: Day One
Details:
- Discussing efficacy and safety of MIRV in FR-alpha high, platinum resistant ovarian cancer
- Outlining the evolution of the companion diagnostics and impacts on trials
- Sharing information about on-going trials and next steps
